Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Raw Materials (2020 - 2025)

Maxcyte (MXCT) has disclosed Raw Materials for 6 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Raw Materials fell 30.53% to $3.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.9 million, a 30.53% decrease, with the full-year FY2024 number at $4.7 million, down 17.16% from a year prior.
  • Raw Materials was $3.9 million for Q3 2025 at Maxcyte, down from $4.1 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $6.0 million in Q1 2023 to a low of $1.6 million in Q3 2021.
  • A 5-year average of $4.6 million and a median of $5.0 million in 2022 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: surged 224.18% in 2022, then crashed 30.53% in 2025.
  • Maxcyte's Raw Materials stood at $2.7 million in 2021, then soared by 110.54% to $5.7 million in 2022, then increased by 0.76% to $5.7 million in 2023, then decreased by 17.16% to $4.7 million in 2024, then decreased by 18.13% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Raw Materials are $3.9 million (Q3 2025), $4.1 million (Q2 2025), and $4.5 million (Q1 2025).